Dr. Pramod Kumar Kuchulakanti

Education Qualifications

• 2020-2021: MA Sanskrit, Osmania University, Hyderabad
• 2013-2015: MBA (Hospital Management), Alagappa University, Tamil Nadu
• 2004-2005: Clinical Training (USA), Fellowship Interventional Cardiology, Washington Hospital Center, Washington, DC
• 1996-1998: Clinical Training (India), SR (Cardiology), King George's, Lucknow
• 1996-1998: DM (Cardiology), King George's Medical College, Lucknow
• 1995-1996: Clinical Training (India), SR (Cardiology), S G P G I, Lucknow
• 1994-1995: Clinical Training (India), SR (Cardiology), S V Institute of Medical Sciences, Tirupati
• 1991-1994: Clinical Training (India), PG (Medicine), Osmania General Hospital, Hyderabad
• 1991-1994: MD (Medicine), Osmania Medical College, Hyderabad
• 1989-1990: Clinical Training (India), Internship, Government General Hospital, Vijayawada
• 1984-1989: MBBS, Siddhartha Medical College, Vijayawada

Experience

• Currently working as a Senior Consultant Interventional Cardiologist at Yashoda Hospitals, Somajiguda
• 2005-2011: Consultant Cardiologist, Director of Cardiac Cath Lab, Wockhardt Hospital, Hyderabad
• 2004-2005: Fellowship in Interventional Cardiology, Washington Hospital Center, Washington DC
• 2003-2004: Research Fellowship in Interventional Cardiology, Washington Hospital Center, Washington DC
• 1999-2002: Interventional Cardiologist, Usha Mullapudi Hospital, Hyderabad, India
• 1998-1999: Junior Consultant, Interventional Cardiology, Apollo Hospitals, Hyderabad, India

Services offered

• Primary Angioplasty & Stenting
• Complex Coronary Interventions
• Structural Heart Interventions (TAVI, TEVAR)
• Balloon Valvuloplasty
• Pacemaker Implantation
• Carotid and Peripheral Angioplasty and Stenting
• ASD/VSD/PDA Device Closure
• Cardiac Catheterization
• Bypass Surgery
• Coronary Angioplasty
• Non-Invasive Cardiology
• 2D and 3D Echo
• Transesophageal Echo
• Stress Testing
• CT Coronary Angiography
• Cardiac MR
• 24 Hour Holter
• Clinical Research & Health Education
• Clinical Trials and Research Related to Coronary Interventions and Restenosis
• Clinical Studies in Relation to Coronary Risk Factors and Drugs to Control Risk Factors
• Conducting Health Education Lectures for General Physicians, Family Physicians and Lay Public to Create Awareness about Coronary Risk Factors and Therapies for CAD

Special Interest and Expertise

• Primary Angioplasty & Stenting, Complex Coronary Interventions LM, Bifurcation, CTO, Vein Graft Interventions
• Calcific Coronary Lesions (Rotablation, Intravascular Lithotripsy and Orbital Atherectomy)
• Coronary Imaging (IVUS, OCT and FFR guided PCI)
• Valve Interventions – Balloon Valvuloplasty, TAVI (Certified as Solo Implanter)
• Pacemaker, ICD and CRT Device Implantation
• Mechanical Circulatory Support

Professional Membership

• Fellow, American College of Cardiology (FACC)
• Fellow, Cardiological Society of India (FCSI)
• Affiliate, Society of Cardiac Angiography and Interventions (SCAI)
• Life Member, Cardiological Society of India (CSI)
• Life Member, Indian Society of Echocardiography (ISE)
• Member, European Association of Percutaneous Coronary Interventions (EAPCI)
• Fellow, European Society of Cardiology (FESC)
• Member and Former President, Lions Club International, Bhagyanagar Branch, Hyderabad, India
• Chairman, Scientific Committee, Basics and Beyond Interventional Cardiology Conference (since 2011)

Research & Publications

• More than 60 peer-reviewed articles and five book chapters have been published in prestigious journals worldwide
• K. Pramod Kumar, J.Shiva Kumar, P.S.Rao. Complete thrombolysis for acute embolic stoke during Coronary angiography. Indian Heart Journal, 1999; 51; 429-431.
• PC Rath, Manoj Agarwal, N.K.Das, T Deb, K.P.Kumar, N.K.Panigrahi. Coronary stenting without Predilatation: an observational study. Indian Heart Journal, 2000; 52: 45-47.
• S.K.Dwivedi, K. Pramod Kumar, R.Gupta, RK Saran, VS Narain, VK Puri. Mega dose Heparin and Streptokinase produce similar TIMI 3 flow at discharge in patients of Acute Myocardial infarction presenting between 7-12 hours. Indian Heart Journal 2000; 52:183-186.
• Kuchulakanti P, Lew R, Waksman R. Mechanisms and Methods to Resolve Edge Effect. J Inv Cardiol 2003; 15:363-6
• Pramod Kuchulakanti. Intracoronary fracture and embolization of a coronary angioplasty balloon catheter: Retrieval by a simple technique. Cathet Cardiovasc Interventions, 2003; 60:425.
• Kuchulakanti P, Waksman R. Repeat Radiation for Recurrent In Stent Restenosis in Patients Who Failed Initial Brachytherapy. J Invasive Cardiol. 2003; 15:732-5.
• Pramod Kuchulakanti, Ron Waksman. A case of Cypher restenosis treated with gamma radiation. Cardiovascular Radiation Medicine, 2004; 4:169-170.
• Pramod Kuchulakanti, Lowell F. Satler, William O. Suddath, et al. Vascular Complications Post Coronary Intervention Correlates with Long-term Cardiac Events. Cathet Cardiovasc Interventions, 2004; 62:181-185
• Pramod Kuchulakanti, Lowell F. Satler, Seung-Woon Rha, Ron Waksman, Case Report: Bivalirudin Associated Intracoronary Thrombosis during Gamma Brachytherapy and Its Experimental Validation in Acute Swine Model. Cathet Cardiovasc Interventions, 2004; 62:209-213.
• Pramod Kuchulakanti, Seung Woon Rha, Edouard Cheneau, Lowell Satler, Augusto Pichard, Kenneth Kent, Ron Waksman. Identification of "vulnerable plaque" using Virtual Histology in angiographically benign looking lesion of Proximal Left Anterior Descending Artery. Cardiovascular Radiation Medicine, 2004; 4:225-227.
• Rajbabu Pakala, Seung-Woon Rha, Pramod Kumar Kuchulakanti et al. Peroxisome Proliferator-Activated Receptor γ: its role in atherosclerosis and restenosis. Cardiovasc Radiat Med 2004: 5:44-8.
• Pramod Kuchulakanti, Seung-Woon Rha, Lowell F. Satler et al. Impact of Major Side Branch on Periprocedural Enzyme Elevation and Long term Outcome in Patients Undergoing PCI and Brachytherapy for In-stent Restenosis. Am J Cardiol, 2004; 93: 1394-97.
• Edouard Cheneau, Daniel Canos, Pramod K. Kuchulakanti. Correlation between Activated Clotting Time and Ischemic and Bleeding Complications after Coronary Angioplasty with bivalirudin. Am J Cardiol. 2004:94:789-92.
• Ron Waksman, Andrew E. Ajani, Augusto D. Pichard, Rebecca Torguson, Ellen Pinnow, Daniel Canos, Lowell F. Satler, Kenneth M. Kent, Pramod Kuchulakanti, Chrysoula Pappas, Louise Gambone, Neil Weissman, Maureen C. Abbott, and Joseph Lindsay. Oral Rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Orbit study. J Am Coll Cardiol. 2004; 44:1386-92.
• Seung-Woon Rha, Pramod K. Kuchulakanti, Rajbabu Pakala et al. Addition of Heparin to Contrast Media is Associated with Increased Bleeding and Peripheral Vascular Complications during Percutaneous Coronary Intervention with Bivalirudin and Drug-Eluting Stent. Cardiovasc Radiat Med 2004; 5:64-70
• Rajbabu Pakala, Pramod Kumar Kuchulakanti, Seung-Woon Rha, et al. Peroxisome Proliferator-Activated Receptorγ: its role in metabolic syndrome. Cardiovasc Radiation Medicine 2004; 5:97-103.
• Seung-Woon Rha, Pramod K. Kuchulakanti, Rajbabu Pakala et al. Angiomax versus Heparin as an Antithrombotic Agent in Patients Treated with Sirolimus-Eluting Stent. Am J Cardiol 2004; 94:1047-1050.
• Pramod Kuchulakanti, Ron Waksman. Therapeutic potential of oral anti-proliferative agents in the prevention of coronary restenosis. Drugs, 2004; 64: 2379-2388.
• Pramod Kuchulakanti, Seung-Woon Rha, Lowell F. Satler, et al. Safety of Percutaneous Coronary Intervention alone in symptomatic patients with moderate and severe valvular Aortic Stenosis and Co existing Coronary Artery Disease - analysis of results in 56 patients. Journal of Inv Cardiol 2004;16:688-691.
• Seung-Woon Rha, Pramod K. Kuchulakanti, Rajbabu Pakala et al. The “Real World” Clinical Practice of Intracoronary Radiation Therapy as Compared to Investigational Trials. Catheter Cardiovasc Intrerv. 2005; 64:61-66.
• Pramod Kuchulakanti, Emmanouil Kapatanakis, Robert Lew et al. Impact of continued hospitalization before Coronary Artery Bypass Grafting in patients who received Clopidogrel prior to Coronary Angiography. Journal of Inv Cardiol 2005; 17:5-7
• Dilcher C, Chan R, Hellinga D, Seabron R, Pakala R, Kuchulakanti PK, Richard R, Chan K, Zhong S, Barry JJ, Waksman R. Effect of ionizing radiation on the stability and performance of the TAXUS Express (2) paclitaxel-eluting stent. Cardiovasc Radiat Med. 2004; 5:136-41.
• Clavijo LC, Kuchulakanti P, Chu WW, Weigold G, Pichard AD, Waksman R, Boyce SW, Satler LF, Kent KM. "Hybrid" approach for the treatment of a giant left main coronary artery aneurysm. Cardiovasc Radiat Med. 2004; 5:153-4
• Seung-Woon Rha, Pramod K Kuchulakanti, Ajani AE et al. Three Year Follow-Up after Intracoronary Gamma Radiation for In-Stent Restenosis in Saphenous Vein Grafts Catheter. Cardiovasc Interv 2005; 65:257-62
• Chu WW, Rha SW, Kuchulakanti PK et al., Selective versus exclusive use of sirolimus-eluting stent implantation in multi vessel coronary artery disease. Catheter Cardiovasc Interv. 2005; 65:473-7.
• Rha SW, Kuchulakanti PK, Pakala Ret al. Bivalirudin versus Heparin as an Antithrombotic Agent in Patients Undergoing Percutaneous Saphenous Vein Bypass Grafts Intervention with Distal protection Device. Am J Cardiol. 2005; 96:67-70.
• Cheneau E, Rha SW, Kuchulakanti PK, et al. Impact of Sirolimus eluting stents on outcomes of patients treated for acute myocardial infarction treated by primary angioplasty. Catheter Cardiovasc Interv. 2005; 65:469-72.
• Kuchulakanti PK, Wolfram R, Torguson R et al., Brachytherapy and Bivalirudin Evaluation Study, Am Heart J. 2005; 150:832-7.
• Kuchulakanti PK, Torguson R, Canos D et al, Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and non-diabetic patients. Am J Cardiol. 2005; 15; 96:1100-6.
• Clavijo L, Yar O, Kuchulakanti PK et al. MRI Evaluation of coronary artery perforation. Cardiovasc Revasc Med. 2005; 6:44-5.
• Kuchulakanti PK, Torguson R, Canos D et al. Optimizing dosimetry with high-dose intracoronary gamma radiation (21 Gy) for patients with diffuse in-stent restenosis. Cardiovasc Revasc Med. 2005; 6:108-12.
• Kuchulakanti PK, Wolfram R, Torguson R et al. Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy. Cardiovasc Revasc Med. 2005; 6:154-9.
• Chu WW, Rha SW, Kuchulakanti PK et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2006; 97:34-7
• Chu WW, Kuchulakanti PK, Rha SW et al. Impact of three or more versus a single sirolimus-eluting stent on outcomes in patients who undergo percutaneous coronary intervention. Am J Cardiol. 2006; 97:606-10
• Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis with Sirolimus and Paclitaxel-Eluting Stents. Circulation 2006
• Pramod Kuchulakanti, John Laird, Robert Dieter, Rebecca Torguson, Ron Waksman. Treatment of Renal In-stent Restenosis with Gamma Radiation – Results of a Single Center Experience. J Vasc Disease Management.
• Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med. 2006; 7:7-11
• Kuchulakanti PK, Torguson R, Chu WW, Canos DA, Rha SW, Clavijo L, Deible R, Gevorkian N, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2006; 97:792-7
• Chu WW, Kuchulakanti PK, Torguson R, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006; 67:595-599
• Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF, Kent KM, Suddath WO, Waksman R, Pichard AD. Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol. 2006; 97:981-3.
• Chu WW, Kuchulakanti PK, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Efficacy of sirolimus-eluting stents as compared to Paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol. 2006; 19:121-5.
• Hassani SE, Chu WW, Wolfram RM, Kuchulakanti PK, Xue Z, Gevorkian N, Suddath WO, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol. 2006; 18:273-7.
• Chu WW, Kuchulakanti PK, Torguson R, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006
• Hassani SE, Wolfram RM, Kuchulakanti PK, Xue Z, Gevorkian N, Suddath WO, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R. Percutaneous coronary intervention with drug-eluting stents in octogenarians: Characteristics, clinical presentation, and outcomes. Catheter Cardiovasc Interv. 2006
• Kuchulakanti PK, Chu WW, Torguson R, Clavijo L, Wolfram R, Mishra S, Xue Z, Gevorkian N, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol. 2006; 98:187-92
• Chu WW, Kuchulakanti PK, Wang B, Torguson R, Clavijo LC, Pichard AD, Suddath WO, Satler LF, Kent KM, Waksman R. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Cardiovasc Revasc Med. 2006; 7:132-5
• Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Hartwig S, Harder C, Rohde R, Heublein B, Andreae A, Waldmann KH, Haverich A. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006; 68(4): 607-17
• Kim SW, Mintz GS, Ohlmann P, Hassani SE, Fernandez S, Lu L, Chu WW, Escolar E, Kuchulakanti PK, Weigold G, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R, Weissman NJ. Frequency and severity of plaque prolapse within Cypher and Taxus stents as determined by sequential intravascular ultrasound analysis. Am J Cardiol. 2006; 98:1206-11.
• Kuchulakanti PK, Waksman R. Sirolimus versus paclitaxel-eluting stents: numero uno, first among equals or equal? Future Cardiology 2006; 2:483-491.
• Clavijo LC, Steinberg DH, Torguson R, Kuchulakanti PK, Chu WW, Fournadjiev J, Satler LF, Kent KM, Suddath WO, Waksman R, Pichard AD. Sirolimus-eluting stents and calcified coronary lesions: Clinical outcomes of patients treated with and without rotational atherectomy. Cath Cardiovasc Interv 2006; 68:873-8.
• Chu WW, Kuchulakanti PK, Torguson R, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Comparison of clinical outcomes of overlapping sirolimus- versus Paclitaxel-eluting stents in patients undergoing percutaneous intervention. Am J Cardiol 2006; 98: 1563-66
• Pallempati S, Kuchulakanti PK. PCI in Acute Myocardial Infarction, which artery to choose? Indian Heart Journal, 2009;61(4):384-5
• Kuchulakanti PK. Rescue PTCA – current status. Indian Heart Journal, 2009;61(5):462-3
• Ashwin B Mehta, Praveen Charndra, Jamshed Dalal et al. One-year clinical outcomes of BioMatrix-Biolimus A9 eluting stent: The e-BioMatrix multicenterpost marketing surveillance registry in India. Indian Heart Journal, 2013:65:593-599
• Pramod Kumar Kuchulakanti, Sateesh Chirde, Raghvender Akkala. Successful treatment of aortic prosthetic valve thrombosis with bolus dose Tenecteplase. Indian Heart Journal, 2014; 66:251-252
• Akkala R, Mallempalli S, Kuchulakanti PK. Successful thrombolysis of left subclavian arterial thrombosis with intravenous bolus dose of tenecteplase. Indian Heart J. 2017 Jan - Feb; 69(1):101-103.
• Pramod K Kuchulakanti, VCS Srinivasarao Bandaru, Anurag Kuchulakanti et al. Subclinical hypothyroidism in heart failure: a study from South India. Br J Cardiol 2019;26:1-5
• Guruprakash A, Giragani S, Kuchulakanti PK et al. Recurrent Pulmonary Arteriovenous Malformation with Embolization. The Cardiologist. 2019 | Volume 1 | Article 1005.
• Pramod Kumar Kuchulakanti, Jaydip Ray Choudhuri, Urmila Anand et al. Association of serum 25-hydroxyvitamin D levels with primary hypertension: a study from south India. Hypertens Res (2020)
• Pramod Kumar Kuchulakanti. ARNI for Cardiovascular Disease-current evidence and future perspectives. Future Cardiology. https://doi.org/10.2217/fca-2019-0089
• Pramod Kumar Kuchulakanti. Left main PCI – Current Evidence, Techniques, Triumph. Indian Journal of Clinical Cardiology. 1(2)86-93:2020
• Jariwala P, Rohit Reddy P, Guruprakash A, Narasaraju K, Pramod Kumar Kuchulakanti. Twelve months clinical outcomes of biodegradable polymer-coated Sirolimus eluting coronary stent in real-world patients: a single center experience. Indian Heart Journal 73 (2021) 114-116.
• Authored Book Chapters
• Pramod Kuchulakanti and Ron Waksman. Brachytherapy, Chapter No. 32, pp 349-366, in Interventional Cardiology, Ed. Spencer B King III, Alan C Yeung, McGraw Hill, New York, 2007.
• Pramod Kuchulakanti. Oral Agents to Prevent ISR (Sirolimus and Glitazones) in Pharmacology in Cath Lab, Ed. Ron Waksman and Andrew Ajani, Blackwell Publishing, Oxford, UK, 2007.
• Pramod Kumar Kuchulakanti. Primary Angioplasty - the State of the Art Management of Acute ST Elevation Myocardial Infarction, Chapter 10, Hand Book on UCAD, An Indian Perspective, Pfizer Company, 2008.
• Pramod Kuchulakanti and Ron Waksman. Chapter 17 - Intracoronary Brachytherapy, Essential Interventional Cardiology (2nd Edition), Ed Michael Norrell, Elsevier, 2008.
• Pramod Kumar Kuchulakanti. Chapter 68, Nebivolol in Hypertension with STEMI, STEMI, A Cardiology Update, First Edition, 2016, Jaypee Publications.

Awards and Achievements

• "Distinguished Best Teacher National Award," ANBAI, Amritasar, Punjab, 2023
• Faculty, Cardiology Society of India
• Reviewer, Future Cardiology
• "Rising Star of Cardiology" by Times of India at Novotel, Hyderabad, March 5, 2017
• Reviewer, Cardiovascular Revascularization Medicine, Elsevier, since 2005
• Editorial Advisor, Indian Heart Journal, since 2015
• Chairman, Scientific Committee, Basics and Beyond-Interventional Cardiology Update 2012, 2013, 2015, 2018, HICC, Novotel, Hyderabad
• Faculty, CHORUS, Seoul, 2011, 2012
• "Best Case Award," TCT Asia Pacific, Seoul, South Korea, 2012
• Faculty, TCT Asia Pacific, Seoul, South Korea, 2012
• Letter of commendation from International President Lion Sid L Scruggs III for community service, 2010-2011
• Faculty, TCT Asia Pacific, Seoul, South Korea, 2011
• "Dhanwantari Award" for patient service, Hyderabad, 2009
• Faculty, Singapore Live 2008, Suntec City, Singapore, March 7-9, 2008
• Faculty, 3rd Acute Myocardial Infarction Course, January 27-29, 2008, New Delhi
• Guest Faculty, Cardiovascular Radiation Therapy 2004, Hilton Washington, Washington, DC
• Dr. S.R. Rao Research Award from the Association of Physicians of India, Hyderabad Chapter, for the work "Transient Myasthenic Syndrome-Clinical and Electrophysiologic Evaluation," 1995

  FAQ'S

1. 1. Why do patients frequently visit Dr. Pramod Kumar Kuchulakanti?
   

   Patients visit Dr. Pramod Kumar Kuchulakanti to receive treatment for various cardiovascular diseases.

2. 2. What is Dr. Pramod Kumar Kuchulakanti's educational qualification?
   

   Dr. Pramod Kumar Kuchulakanti holds the following qualifications: MD, DM, FACC, FESC, FCSI, Interventional Fellowship (USA), MBA (Hospital Management).

3. 3. What does Dr. Pramod Kumar Kuchulakanti specialise in?
   

   Dr. Pramod Kumar Kuchulakanti is a Senior Consultant Interventional Cardiologist who specialises in performing various Complex Coronary Interventions such as Saphenous Vein Grafts with Distal Protection Devices, Left Main Interventions, Bifurcations, Chronic Total Occlusions, Primary PTCA during Cardiogenic Shock, Recurrent Ventricular Arrhythmias, and Complete Heart Block, among others.

4. 4. Where does Dr. Pramod Kumar Kuchulakanti practice?
   

   Dr. Pramod Kumar Kuchulakanti practices at Yashoda Hospitals, Somajiguda.

5. 5. How can I book Dr. Pramod Kumar Kuchulakanti’s appointment?
   

   You can schedule an appointment with Dr. Pramod Kumar Kuchulakanti for both an Online Video Consultation and an OPD Consultation by visiting his profile on Yashoda Hospitals.